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ABSTRACT 
The purpose was to study the anti-angiogenic effect of adipose-derived mesenchymal stem/stromal cells (ADMSCs) on 
experimentally induced corneal injuries. Corneal neovascularization (NV) was induced by incising and subsequently 
suturing the corneal surface in 32 New Zealand rabbits. Following suturing, the rabbits were randomly allocated into 2 
groups, and received either phosphate-buffered saline (PBS) (control) or ADMSCs, both administered via three different 
routes. Digital images of the cornea were obtained two weeks post-incision to measure the area of neovascularized 
cornea. Tumor necrosis factor (TNF) was immunohistochemically assessed in the both groups. The corneal tissue was 
evaluated for vascular endothelial growth factor (VEGF). The extent of corneal NV in all eyes was assessed 
photographically by an independent observer. Fourteen days after the incisions, the degree of corneal NV was 
substantially decreased in the ADMSC-treated group (1.87 ± 0.9 mm2, 1.4 % ± 0.67 % of corneal surface) compared to the 
control and PBS-treated group (4.66 ± 1.74 mm2, 3.51 % ± 1.31 %, p < 0.001). ADMSCs significantly decreased injury-
induced corneal NV in New Zealand rabbits two weeks post-treatment. This strategy has potential for use in the control 
of corneal NV in vivo. 
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INTRODUCTION
The cornea is the most important refractive structure of 
the eye due to its unique arrangement of histological 
components and hemispherical shape [1]. As an 
avascular tissue, the cornea is an immunologically 
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privileged structure [2, 3], and owes its clarity to its 
unique arrangement of stromal collagen fibrils and lack 
of vascularization, at least centrally. Corneal 
transparency can be maintained through a dynamic 
balance between pro- and antiangiogenic mechanisms 
[4, 5]. Corneal neovascularization (NV) constitutes a 
defense mechanism against harmful agents [6] and 
diseases [7], and facilitates transfer of neutrophils, 
macrophages, dendritic cells, lymphocytes and cytokines 
closer to sites of injury [8]. During NV, endothelial cells 
proliferate, migrate and form new vessel branches [9]. 
Release of several angiogenetic mediators such as 
transforming growth factor (TGF) [10], galectin-3 [11], 
angiotensin and matrix metalloproteinases (MMPs) [12] 
contributes to multiple aspects of corneal NV [13]. 
Enhanced production of proangiogenic factors such as 
vascular endothelial growth factor (VEGF) [14, 15], 
angiopoietins [16] and tumor necrosis factor (TNF) favors 
angiogenesis [17]. After healing, the blood vessels leave 
empty structures known as ghost vessels [18]. 
Recently, it has been indicated that mesenchymal stem 
cells (MSCs) attenuate NV after insults such as burns and 
other injuries. These cells interact with host cells both 
directly or by paracrine signaling. Attenuated VEGF 
activity has been reported in MSC-treated rats [19], 
however, Watt et al. reported opposing results, 
suggesting that MSCs promote 
vasculogenesis/angiogenesis [20, 21]. To clarify this 
contradiction, we examined the antiangiogenic 
properties of MSCs in a rabbit model.  
Besides their reported antimicrobial effects, MSCs also 
exhibit adjuvant anti-inflammatory properties [22]. 
Neovascularization is inhibited through suppression of 
proangiogenic MMP-2 and induction of gene expression 
of the antiangiogenic factor thrombospondin-1 (TSP-1) 
[23], a VEGF inhibitor [19]. The corneal microenvironment 
promotes the antiangiogenic role of MSCs, which is 
important for optimal recovery without corneal scars and 
opacities. This is in contrast to other tissues where 
revascularization is also mediated by MSCs (i.e., the skin), 
where scarring is vital for the healing process [22].  
In the present study, we focused on the antiangiogenic 
effects of adipose-derived MSCs (ADMSCs) in modifying  
the consequences of mechanical corneal injuries in a 
rabbit model. 
MATERIAL AND METHODS 
Culture of rabbit ADMSCs  
This interventional animal study was started in July 2015 
and concluded in September 2018. ADMSCs were 
secluded as previously described [24]. Briefly, the 
animals were intramuscularly anesthetized by 30–50 
mg/kg ketamine and 3–5 mg/kg xylazine (both from 
Lyon, France). Following surgical ablation from the 
inguinal region the fat pad was washed with phosphate-
buffered saline and treated for 1 h at 37 °C with 
collagenase type 1 (Sigma–Aldrich, St Louis, The USA) 
under agitating. After introducing phosphate-buffered 
saline (PBS) to the tube which was left standing, the 
lower clear layer with ADMSCs was collected.  
The mesenchymal cells were cultured for no more than 5 
passages (duplications) in a chamber with antibiotics. 
Characterization of the MSCs  
Identification of MSC’s specific markers was performed 
by flow cytometry. Briefly, cells were obtained with 
centrifugation and then stained against CD44 and CD73 
(BD Pharmingen, The USA) [25]. A FACS Calibur device 
(Becton Dickinson, Franklin Lakes, The USA) was used. To 
test the differentiation capacity of MSCs, osteogenic or 
adipogenic medium (Thermo Fisher Scientific, MA, The 
USA) was added to the culture for approximately 30 days 
with a medium change every 3 days. Successful 
differentiation was assessed via alizarin red and oil red 
staining. 
Animal model 
Thirty-two New Zealand rabbits, each weighing 2500-
3500 grams, were used in this experimental study. All the 
animals were kept in a specially designed, well-ventilated 
facility under stable temperature and humidity with a 
successive 12-hour  light/dark cycle and fed ad libitum. 
All principles of the ARVO Statement were implemented 
[26]. All procedures and experimental designs of the 
study were reviewed and authorized by the appropriate 
state institutions (Ethics Committee and Committee of 
Veterinary Medicine of the Aristotle University of 
Thessaloniki). The study was conducted in the Surgery 
Unit of the School of Veterinary Medicine. Before the 
study, all the rabbits underwent a thorough ophthalmic 
examination to exclude those with ocular pathology.  
A previously described model of penetrating injury [27, 
28] was modified to assess the effects of MSCs on 
corneal wounding and NV. All the animals were 
anesthetized by intramuscular injection of 75–100 μg/kg 
dexmedetomidine (Dexdomitor, 0.5 mg/mL, Zoetis 
Hellas) and 15 mg/kg ketamine (Imalgene 1000, 100 
mg/mL, Merial, France) and instillation of 1–2 drops of 
topical anesthetic (proxymetacaine hydrochloride 0.5 %, 
Alcaine, Alcon Laboratories Hellas, Greece). The ocular 
surface and conjunctival fornix were cleaned and 
disinfected with a mild antiseptic solution containing 
0.5% aqueous povidone–iodine, followed by placement 
of an eyelid retractor. Corneal diameter was measured to 
exclude animals with values differing from the mean. 
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A linear, full-thickness, 4-mm corneal incision was made 
with a disposable 15° ophthalmic knife adjacent to the 
superior corneolimbal junction and cautiously advanced 
centrally to avoid iris prolapse. The wound was securely 
sutured with two interrupted 10-0 nylon sutures 
(DemeTECH Co, Miami, The USA) parallel to the limbus 
and embedded (Figure 1). Wound integrity was tested 
using an ophthalmic strip containing fluorescein (Seidel 
test negative). The same investigator performed all 
surgeries to enhance reproducibility. Following suture 
setting and eye drop administration, animals were 
randomly selected to receive either ADMSCs (group 1; n 
= 16) or PBS (group 2, control; n = 16) via the same 
routes. In total, 2 × 106 ADMSCs in 1 mL of PBS was 
applied to each cornea via three routes to increase the 
amount of ADMSCs infused and hence boost their 
effectiveness. A corneal intrastromal micropocket was 
created into the wound edges with an ophthalmic knife 
and 1/3 of the ADMSCs were infused. An ophthalmic 
microsurgical angular cannula was inserted into the 
cornea at the midstromal level of both sides of the 
incision, forming a deposit of ADMSCs. Furthermore, 1/3 
of the ADMSCs were injected subconjunctivally. Finally, 
the remaining ADMSCs were applied locally on the 
wounded area (Figure 1). All the animals were 
administered a topical antibiotic (0.3% Ofloxacin; 
Oxatrex, Zwitter, Athens, Greece) and 1 % cyclopentolate 
HCL (Cyclogyl, Alcon, Greece) every 6 h on the first 
postoperative day, and then twice daily for the first 
week. Meloxicam (0.2 mg/kg subcutaneously; Metacam, 
5 mg/mL, Boehringer Ingelheim, Germany) was also 
administered postoperatively and then once a day for the 
next 5 days. All sutures remained in place until 
photographs were taken. The length of corneal NV was 
measured from the limbal vascular plexus to its distant 
point (height). The contour of new sprouting vessels was 
also measured. All photographs were processed with 
Klonk Image Measurement version 16.1.14 (Image 
Measurement Co, Cheyenne, The USA). The animals were 
euthanized on day 14 when NV was prominently 
developed [29] and the eyeballs were enucleated. 
Histology 
The eyeballs were dissected and after formalin fixation 
dehydrated through 70%, 80%, and 95% alcohol followed 
by three changes of 100% alcohol and cleaning through 
two changes of xylene. They were dissected into 4-µm–
thick slices, stained with hematoxylin and eosin (H&E) 




The paraffin blocks with the eye tissue sections (4 μm) 
embedded, were used to implement 
immunohistochemistry with mouse anti-VEGF and anti-
TNF antibodies (both from Abcam Biotechnology, 
Cambridge, The United Kingdom). Briefly, the eye tissue 
sections were incubated in a 3% H2O2 solution in 
methanol. Antigen recapture was performed by using 10 
mM citrate buffer followed by incubation at 100°C. After 
incubation in blocking buffer, diluted primary antibodies 
were added to the sections for 1 h, followed by 
incubation with biotinylated secondary antibodies for 30 
min. The expression of VEGF and TNF was revealed using 




Figure 1. Image of a rabbit cornea immediately after adipose-derived 
mesenchymal stem/stromal cell (ADMSC) application. Corneal edema 
and conjunctival chemosis causing deformation of eye tissue and 
suture stretching are seen. 
 
Statistical analysis 
Using SPSS software version 20.0 for Windows (SPSS Inc., 
Chicago, IL, The USA) parametric statistical analyses were 
performed, after assessment of data normality with the 
Kolmogorov–Smirnov test. Independent-samples t-test 
was used to evaluate the differences in corneal NV distal 
point (height) and area. Levene’s test was performed to 
test the equality of group variances. Differences were 
considered significant when p-values were less than 0.05.  
RESULTS 
Characterization of the administered ADMSCs 
The cultured ADMSCs displayed a spindle-like, adult 
ADMSC morphology (Figure 2). Cells were additionally 
characterized based on CD44/CD73 markers detection 
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(Figure 2). The ability of ADMSCs to differentiate into 
adipocytes and osteocytes was confirmed after 
completion of differentiation (Figure 3). 
The Effect of ADMSCs on Corneal Neovascularization 
Neovascularization was observed in all injured corneas. 
Nevertheless, significantly less of the corneal surface was 
covered with neovascular tissue in ADMSC-infused eyes 
compared to control eyes (Table 1), as evidenced in 
photographs taken 14 days following suture placement. In 
the control, PBS-infused group, consequential compound, 
centripetal vessels emerged from the limbal area. In the 
ADMSC-treated group, the bulbar conjunctiva adjacent to 
the injury was mildly hyperemic, whereas a fully hyperemic 
pattern was established in the control group (Figure 4).  
 





Figure 3. Morphological Depiction of Adipose-Derived Mesenchymal Stem/Stromal Cell (ADMSC) Differentiation. (I, Osteogenesis Negative Control; II, 
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Table 1. Corneal Neovascularization in Eyes Treated With Adipose-Derived Mesenchymal Stem/Stromal Cells and Those of the Control Group 
Group Measurement Mean ± SD Standard error 95 % CI of the mean p-value 
ADMSC-treated Distal point (mm) [30] 0.98 ± 0.30 0.07 0.83–1.12 p < 0.001 
Area (mm2) 1.87 ± 0.90 0.21 1.44–2.30 
Control Distal point (mm) [30] 2.88 ± 0.58 0.15 2.58–3.18 
Area (mm2) 4.66 ± 1.74 0.44 3.78–5.54 
Abbreviations: ADMSC, adipose-derived mesenchymal stem/stromal cell; SD: standard deviation; CI: confidence interval (p < 0.001, t-test). 
 
 
No corneal opacities or scars were observed in either 
group as the wound was surgically incised and sutured 
without delay. No immune rejection occurred in any of 
the eyes of the ADMSC-treated group. The area and 
distal point of corneal NV in both groups are depicted in 
Figure 5. The corneal NV distal point from limbus (height) 
in group 1 (ADMSC-treated) (0.98 ± 0.3 mm) was 
significantly lower than that in group 2 (control) (2.88 ± 
0.58 mm, p < 0.001). Furthermore, the corneal NV 
surface was significantly reduced in group 1 (1.87 ± 0.9 
mm2) compared to that in group 2 (control) (4.66 ± 1.74 
mm2, p < 0.001) (Table 1). 
Histopathological and Immunohistochemical Findings 
In the control group, the injured corneas exhibited 
severe NV and disorganized stroma with severe edema. 
Although mild edema was noted in the ADMSC-treated 
group following administration, the surface appeared 
smooth and exhibited intact, almost physiologically 






Figure 4. Representative images of angiogenesis in group 1 (adipose-derived mesenchymal stem/stromal cell [ADMSC]-treated) vs group 2 (control). (a) 
Eyes treated with ADMSCs exhibited limited (1.87 mm2 ± 0.90 mm2) neovascularization (NV) 14 days after ADMSC treatment. (b) Corneal NV in the 
control group 14 days after corneal injury (4.66 mm2 ± 1.74 mm2; p < 0.001, t-test). Corneal NV consisted of dense vessels emerging from pericorneal 
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Figure 5. Extent of corneal neovascularization (NV) in group 1 (adipose-derived mesenchymal stem/stromal cell [ADMSC]-treated) vs. group 2 (control) 
14 days after corneal injury. Interquartile range demonstrating the corneal NV distal point (height) and area in the ADMSC-treated group vs. the control 







Figure 6. Moderate edema was observed in the eyes of the control group (a). H&E staining showing that the corneas of adipose-derived mesenchymal 
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Figure 7. Vascular endothelial growth factor (VEGF) immunostaining of rabbit corneal sections. VEGF staining was intense in control eyes presenting 
corneal NV, x200 (a), whereas no capillaries were detected in adipose-derived mesenchymal stem/stromal cell (ADMSC)-treated corneas, x200 (b); bar 
= 50 μm. 
 
Immunostaining for VEGF and TNF was performed to 
identify the presence of corneal NV and inflammation, 
respectively. In contrast to that observed for control eyes, 
no VEGF staining was detected after induction of corneal 
injury with ADMSC treatment, indicating the beneficial 
effect exerted by administered cells in decreasing 
pathological NV (Figure 7). Additionally, TNF staining was 
also not detected in ADMSC-treated corneas, whereas its 
expression was detected in corneal epithelium and stroma 
of eyes in the control group (Figure 8). No TNF-positive cells 
were represented, demonstrating a limited inflammatory 




Figure 8. Tumor necrosis factor (TNF) immunolocalization in epithelial and stromal cells in eyes from the control group, x200 (a). No TNF-positive cells 
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DISCUSSION 
In the present study, we used an injury-induced NV 
rabbit model to examine the anti-angiogenetic effects of 
ADMSCs in the cornea. We evaluated their ability to 
reduce corneal NV when administered via three 
combined routes. Our results indicate that the area of 
corneal NV in the ADMSCs-treated eyes is significantly 
reduced compared to the control group following injury 
to cornea.  
In 2011, approximately 150,000 penetrating keratoplasty 
surgeries related to ocular surface pathology were 
performed worldwide [31]. Neovascularization may 
compromise the cornea’s normal immunological 
privilege, leading to rejection and subsequent graft 
failure [32]. Corneal surgery and other injuries may 
induce the emergence of new vessels from the limbal 
arcade, involving the whole cornea, which may 
subsequently compromise vision.  
Mesenchymal stem/stromal cells are multipotent cells 
with antiangiogenic properties [23]. Oh et. al  
demonstrated that infusion of human MSCs into mice 
greatly affected survival of allogeneic corneal transplants 
[33]. The results of the present study indicated that 
allogeneic MSCs significantly reduce corneal NV when 
applied in a rabbit model of corneal injury.  
Different routes of administration have been used for 
MSC transplantation, such as intrastromal injection [34], 
subconjunctival administration [35], systemically [36], 
with nanofiber scaffolds [37], and into the anterior 
chamber [28]. Ghazaryan et al. suggested that 
subconjunctival injection overcomes the hurdles of 
amniotic membrane-associated MSC transplantation and 
reduces VEGF levels, resulting in better outcomes [38]. In 
our model, MSC applied by three different routes 
effectively inhibited the formation of new vessels when 
administered immediately after incision.  
Mesenchymal stem/stromal cells secrete soluble 
molecules that inhibit angiogenesis and reduce the levels 
of VEGF [23] via a paracrine signaling process, with a 
concomitant upregulation of TNF-stimulated gene-6 
(TSG-6) [39]. Several studies investigating vascular and 
arterial diseases have shown that MSC paracrine activity 
may be mediated through exosome secretion [30, 40, 
41]; however, the associated mechanisms remain 
unknown. 
Application of MSCs using local subconjunctival injection 
stimulates the therapeutic potential of wounded corneas 
without corneal inflammatory cell infiltration [35]. Song 
et. al. found that intravenous injection (systemic 
administration) of bone marrow-derived MSCs induced a 
prominent reduction in corneal NV and levels of VEGF 
[42]. In this study, we administered ADMSCs by infusion 
(local administration). Consistent with the findings of 
Song et al, the extent of NV was significantly lower in 
ADMSC-treated corneas than controls, indicative of 
reduced VEGF levels. Immunohistochemical data showed 
that VEGF and TNF were expressed in the corneal 
epithelium and stroma of the control group, but not in 
those of the ADMSC-treated group. In agreement with 
our findings, other studies have also reported that TNF is 
associated with corneal NV through induction of 
vasodilatation and leukocyte extravasation [43-45]. 
Inoculation of MSCs after chemically induced corneal 
injury has also been reported to be more effective than 
topical application, possibly because direct contacts 
amongst cells enhance the anti-inflammatory properties 
of cytokines following MSC inoculation [23]. 
Transplanted MSCs may differentiate into keratocytes or 
other cell types such as epithelial progenitor cells, 
corneal endothelial cells, or myofibroblasts. An 
alternative mechanism is that viable epithelial cells 
around the wound would be induced to multiply and 
contribute to healing, masking the deficits of the limbus. 
The latter effect of MSCs can reportedly be mediated by 
growth factors such as VEGF, epidermal growth factor 
(EGF) and TGF-β [19, 23, 34]. Based on the above data, 
we suggest that MSCs can be used as an alternative 
therapy in cases where other antiangiogenic therapies 
have failed. 
Our study indicated that rabbit ADMSCs preserve their 
antiangiogenic properties for up to 5 duplications. 
Wagner et al [46]. reported that MSC self-renewal rate 
declines after three months in cell culture, eventually 
reaching senescence (Hayflick limit). This is a key factor in 
the use of MSCs, as they should be at an early stage to 
exert their unique therapeutic effects. A recent study 
[28] showed that application of young MSCs (after three 
passages) was effective to inhibit corneal scarring after 
penetrating injury in rat corneas. ADMSCs also preserve 
the potential to differentiate through a well described 
procedure into corneal epithelial cells, demonstrating 
their ability for biomedical engineering [47, 48]. 
Numerous studies on animal models of chemically 
induced injury have demonstrated the beneficial effect 
exerted by MSCs in corneal wound healing [49, 50]. 
However, little evidence exists regarding mechanically-
induced corneal injuries which form a sizeable part of in 
vivo corneal pathology [28]. 
In our experimental setting, we used a well-described 
model of penetrating injury to induce corneal NV. We 
investigated alternative approaches by combining three 
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types of local MSC application. Our study supports that 
ADMSCs infusion via three alternative routes may have a 
beneficial role in corneal NV through modulation of VEGF 
and TNF secretion. Additionally, ADMSCs can be readily 
obtained and transplanted, at least in our experimental 
model (rabbit). To the best of our knowledge, this is the 
first time that ADMSCs have been applied using three 
different paths and techniques to successfully reduce and 
control corneal NV following mechanical corneal injury. 
A limitation of our study was restricted number of 
rabbits. The corneal incision was promptly sutured and 
no scar tissue was produced, failing to demonstrate 
ADMSCs efficacy in corneal transparency following 
wound healing. Another limitation was failure to identify 
whether the transplanted cells were differentiated into 
corneal host cells. 
Further studies with sufficient number of animals are 
required for the assessment of MSCs efficacy in ocular 
pathology. Additional clinical trials must be meticulously 
performed to assess the minimum effective number of 
MSCs and possible adverse events before the patient’s 
own MSCs may be transferred in selected cases when the 
patient’s vision is compromised [51]. 
CONCLUSION 
Local ADMSC administration can lead to significant 
inhibition of corneal NV in traumatically induced corneal 
NV in rabbits. To elucidate the practical clinical utility, 
further research is needed to standardize the effective 
ADMSC dosage, frequency of administration and ideal 
mode of application. 
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